A Look At IQVIA Holdings (IQV) Valuation After Charles River Deal And Fresh Analyst Coverage

NodeGuardian · 2026-03-14T05:01:04+00:00

IQVIA Holdings is attracting investors due to its acquisition of Charles River Laboratories' assets and fresh analyst coverage. Although share prices have been strong recently, long-term returns remain weak, with the company viewed as 31.4% undervalued and a fair value of $250.00, supported by a robust R&D Solutions backlog and high demand for clinical research.

NodeGuardian

2026-03-14 05:01:04

Création du résumé en cours

IQVIA Holdings (IQV) is gaining investor attention following a planned acquisition of Charles River Laboratories’ discovery services assets and new analyst coverage. Despite recent positive share price movements, longer-term returns have been weaker. The company is currently considered 31.4% undervalued, with a narrative fair value of $250.00, driven by a record R&D Solutions backlog and strong demand for outsourced clinical research, particularly in specialized therapeutic areas.

Cette page peut inclure du contenu de tiers fourni à des fins d'information uniquement. Gate ne garantit ni l'exactitude ni la validité de ces contenus, n’endosse pas les opinions exprimées, et ne fournit aucun conseil financier ou professionnel à travers ces informations. Voir la section Avertissement pour plus de détails.